Opportunity Information: Apply for PAR 24 271
The NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00, Clinical Trial Not Allowed) is an NIH funding opportunity (PAR-24-271; CFDA 93.866) run by the National Institute on Aging. Its central aim is to strengthen and diversify the translational research workforce focused on Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). The program is framed as a “pathway to independence” award, meaning it is intended to help advanced postdoctoral researchers move from mentored training into an independent research position with their own research program. The long-term objective is to expand the pool of translational scientists from diverse backgrounds who are prepared to contribute to, and eventually lead, interdisciplinary and team-science efforts addressing AD/ADRD treatment, prevention, early detection, and disease management and care.
A key feature of this NOFO is its explicit emphasis on translational research skills and experiences that can be applied across the AD/ADRD spectrum. The opportunity is broad in scientific scope: it supports work ranging from population-based and epidemiologic studies to research that may inform or enable new diagnostics and therapeutics, and it explicitly includes behavioral and social research. Importantly, the focus is not just on producing a set of research results during the award period, but on building the candidate’s capability to operate as an independent translational investigator in AD/ADRD. The award is meant to support highly trained early career researchers as they strengthen their expertise, publication record, and independence, positioning them for a faculty or other independent research role and for competitive future funding.
This NOFO also draws a bright line around clinical trial leadership. It is labeled “Clinical Trial Not Allowed,” which means the candidate’s proposed project cannot involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. However, the announcement makes room for valuable clinical trial exposure: candidates are allowed to propose a research experience within a clinical trial as long as the trial is led by a mentor or co-mentor. In practice, this lets applicants gain hands-on translational and clinical research experience (for example, working with trial data, biospecimens, recruitment frameworks, or trial-related mechanistic studies) without being the responsible party directing the clinical trial itself.
Eligibility is wide on the institutional side, reflecting NIH’s intent to make the mechanism accessible across many sectors and organization types. Eligible applicants include public and private institutions of higher education, nonprofits (both 501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special district), as well as independent school districts and public housing authorities/Indian housing authorities. Native American tribal governments (federally recognized) and tribal organizations (other than federally recognized tribal governments) are also included. The NOFO additionally highlights categories of organizations often associated with serving underrepresented groups or specific communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations and eligible federal agencies. While the document lists “Non-domestic (non-U.S.) Entities (Foreign Organizations)” among other eligible applicant types, it also explicitly states that non-domestic entities are not eligible to apply, and that non-domestic components of U.S. organizations are not eligible. At the same time, it permits foreign components as defined by NIH policy, meaning a U.S.-based applicant organization may be able to include certain foreign activities or collaborations if they meet NIH’s definition and requirements for foreign components.
From an administrative perspective, this is a discretionary grant opportunity under the NIH umbrella. The opportunity was created on 2024-09-04, and the listed closing date is 2027-07-12, indicating a multi-year window during which applications may be accepted according to NIH submission cycles and any stated receipt dates in the full announcement. The award ceiling and expected number of awards are not specified in the provided source details, which is common for NIH career development announcements where budgets and award counts can depend on appropriations, institute priorities, and the number of meritorious applications in a given round.
Overall, this NOFO is best understood as an NIH career transition mechanism aimed at advanced postdocs who are building a translational AD/ADRD research trajectory and who also align with the program’s diversity-oriented workforce goal. It supports the final stretch of mentored development and the leap to independence, encourages interdisciplinary and team-based translational work spanning biomedical, clinical-adjacent (without trial leadership), behavioral, and social science approaches, and seeks to grow the next generation of independent investigators equipped to push forward progress in Alzheimer’s disease and related dementias.Apply for PAR 24 271
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2024-09-04.
- Applicants must submit their applications by 2027-07-12.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00, Clinical Trial Not Allowed) (PAR-24-271)
What is this funding opportunity?
This is an NIH funding opportunity from the National Institute on Aging (NIA) called the Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). It uses the K99/R00 career transition award structure and is identified as PAR-24-271 (CFDA 93.866).
What is the main goal of the program?
The central aim is to strengthen and diversify the translational research workforce focused on AD/ADRD. The program is designed to help advanced postdoctoral researchers transition from mentored training into an independent research position leading their own research program.
Who is the award intended for?
It is intended for advanced postdoctoral researchers who are preparing to become independent translational investigators in AD/ADRD and who align with the program’s diversity-oriented workforce goal.
What does “pathway to independence” mean in this context?
“Pathway to independence” means the award is structured to support a move from a mentored phase of career development into an independent research role. The emphasis is not only on completing a research project, but also on building the applicant’s skills, expertise, publication record, and readiness to compete for future funding as an independent investigator.
What kinds of research does this opportunity support?
The scientific scope is broad and focused on translational research across the AD/ADRD spectrum. Supported work can range from population-based and epidemiologic studies to research that may inform or enable new diagnostics and therapeutics, and it explicitly includes behavioral and social research.
Does the program focus only on research results?
No. A key emphasis is building the candidate’s capability to operate as an independent translational investigator in AD/ADRD, including gaining translational research skills and experiences that can be applied across treatment, prevention, early detection, and disease management and care.
What is meant by “translational research” in this announcement?
Based on the description provided, translational research here is framed broadly as research that can move knowledge toward improved AD/ADRD outcomes, including work that supports treatment, prevention, early detection, diagnostics, therapeutics, and disease management and care, and that can span biomedical, behavioral, and social science approaches.
Are clinical trials allowed under this NOFO?
The NOFO is labeled “Clinical Trial Not Allowed.” This means the proposed project cannot involve the candidate leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.
Can an applicant get clinical trial experience at all?
Yes. The announcement allows a research experience within a clinical trial as long as the clinical trial is led by a mentor or co-mentor. This permits hands-on exposure to clinical trial-related work (for example, using trial data, biospecimens, recruitment frameworks, or trial-related mechanistic studies) without the applicant being responsible for directing the clinical trial.
What is the long-term objective of the program?
The long-term objective is to expand the pool of translational scientists from diverse backgrounds who are prepared to contribute to, and eventually lead, interdisciplinary and team-science efforts addressing AD/ADRD treatment, prevention, early detection, and disease management and care.
Does this program encourage interdisciplinary or team science?
Yes. The stated intent includes preparing awardees to contribute to and eventually lead interdisciplinary and team-science efforts in AD/ADRD.
What types of organizations are eligible to apply?
Eligible applicants include a wide range of U.S.-based organization types, including public and private institutions of higher education; nonprofits (501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); small businesses; and multiple levels of government (state, county, city/township, special district). The list also includes independent school districts and public housing authorities/Indian housing authorities, as well as Native American tribal governments (federally recognized) and tribal organizations (other than federally recognized tribal governments).
Are minority-serving institutions and community-based organizations included as eligible applicants?
Yes. The NOFO highlights organizational categories commonly associated with serving underrepresented groups or specific communities, including HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), and also mentions faith-based or community-based organizations as eligible.
Are foreign organizations eligible to apply directly?
No. While the eligibility list includes “Non-domestic (non-U.S.) Entities (Foreign Organizations)” among other types, the text also explicitly states that non-domestic entities are not eligible to apply.
Are non-domestic components of U.S. organizations eligible?
No. The provided information explicitly states that non-domestic components of U.S. organizations are not eligible.
Are any international activities allowed at all?
Yes, potentially. The NOFO permits foreign components as defined by NIH policy. This suggests a U.S.-based applicant organization may include certain foreign activities or collaborations if they meet NIH’s definition and requirements for a foreign component.
Which NIH Institute runs this opportunity?
This opportunity is run by the National Institute on Aging (NIA), under NIH.
What is the CFDA number listed for this opportunity?
The CFDA number provided is 93.866.
Is this a discretionary grant?
Yes. The opportunity is described as a discretionary grant opportunity under the NIH umbrella.
When was this opportunity created, and when does it close?
The opportunity was created on 2024-09-04, and the listed closing date is 2027-07-12. Applications are expected to be accepted across NIH submission cycles within that multi-year window, consistent with any receipt dates in the full announcement.
Is the maximum award amount (award ceiling) provided?
No. The award ceiling is not specified in the provided information.
Is the expected number of awards provided?
No. The expected number of awards is not specified in the provided information.
Why might the award ceiling or number of awards be unspecified?
The provided description notes this is common for NIH career development announcements, where budgets and award counts can depend on appropriations, institute priorities, and the number of meritorious applications in a given round.
What kinds of AD/ADRD impact areas are emphasized?
The program description emphasizes preparing investigators to address AD/ADRD treatment, prevention, early detection, and disease management and care.
Does this opportunity support behavioral and social research related to AD/ADRD?
Yes. The scope explicitly includes behavioral and social research as part of the translational research spectrum supported by the program.
Does the opportunity allow research that informs diagnostics and therapeutics?
Yes. The scope includes research that may inform or enable new diagnostics and therapeutics, alongside other translational approaches.
Is the award primarily about training or about launching an independent program?
It is positioned as both: it supports the final stretch of mentored development while also enabling the transition to independence, with the intent that awardees become competitive for independent positions and future funding as translational AD/ADRD investigators.
Browse more opportunities from the same category: Health
Next opportunity: Management Development for Minorities and Women in Corrections training
Previous opportunity: Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 24 271
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 24 271) also looked into and applied for these:
| Funding Opportunity |
|---|
| Fiscal Year 2025 Health Center Controlled Network (HCCN) Cooperative Agreements Apply for HRSA 25 018 Funding Number: HRSA 25 018 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Partnership for National Maternal and Child Health (MCH) Leadership Apply for HRSA 25 028 Funding Number: HRSA 25 028 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Section 206 of the Consolidated Appropriations Act, 2024: State Planning Grants to Promote Continuity of Care for Medicaid and CHIP Beneficiaries Following Incarceration Apply for CMS 2T2 25 001 Funding Number: CMS 2T2 25 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $5,000,000 |
| USAID integrated Delivery of Tuberculosis Service (iDOTS) Activity Apply for 72062024RFA00007 Funding Number: 72062024RFA00007 Agency: Nigeria USAID-Abuja Category: Health Funding Amount: $45,000,000 |
| Community and Organizational Resilience and Empowerment to Reduce, manage, and mitigate the risk (of emerging and re-emerging) Infectious Diseases (CORE2RID) Apply for 72048624R00003 Funding Number: 72048624R00003 Agency: Thailand USAID-Bangkok Category: Health Funding Amount: Case Dependent |
| Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed) Apply for RFA AG 25 032 Funding Number: RFA AG 25 032 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries (LMICs) for Aging and Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research (R03 Clinical Trial Not Allowed) Apply for RFA AG 25 031 Funding Number: RFA AG 25 031 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| State-based Healthcare Extension Cooperatives to Accelerate Implementation of Actionable Knowledge into Practice (U19) Apply for RFA HS 24 004 Funding Number: RFA HS 24 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R01 Clinical Trial Not Allowed) Apply for RFA DE 25 001 Funding Number: RFA DE 25 001 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R21 Clinical Trial Not Allowed) Apply for RFA DE 25 002 Funding Number: RFA DE 25 002 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| RFI for SOPHI Apply for RFI 442 24 006 Funding Number: RFI 442 24 006 Agency: Cambodia USAID-Phnom Penh Category: Health Funding Amount: $35,000,000 |
| Emergency Department Substance Use Surveillance System Apply for EDS EDS 24 001 Funding Number: EDS EDS 24 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $150,000 |
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 24 275 Funding Number: PAR 24 275 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Coordinating Center to Support Consortium for Neuroscience Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research in Low- and Middle-Income Countries (LMICs) (U24 Clinical Trial Not Allowed) Apply for RFA AG 25 014 Funding Number: RFA AG 25 014 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Health Systems Strengthening (HSS) Activity Apply for 72038624RFA00004 Funding Number: 72038624RFA00004 Agency: India USAID-New Delhi Category: Health Funding Amount: $20,000,000 |
| Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional) Apply for RFA MD 24 012 Funding Number: RFA MD 24 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID Accelerator Activity Apply for 72066024RFA00006 Funding Number: 72066024RFA00006 Agency: Democratic Republic of the Congo USAID-Kinshasa Category: Health Funding Amount: $90,500,000 |
| USAID Multi Sector Nutrition in the Democractic Republic of Congo Apply for 72066024RFI00007 Funding Number: 72066024RFI00007 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| Early Psychosis Intervention Network (EPINET): Learning Health Care Research to Improve Mental Health Services and Outcomes (P01 Clinical Trial Optional) Apply for RFA MH 25 200 Funding Number: RFA MH 25 200 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed) Apply for RFA AI 24 065 Funding Number: RFA AI 24 065 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 24 271", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.